Covetrus, Inc. (NASDAQ:CVET) insider Dustin Finer sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, June 8th. The stock was sold at an average price of $27.86, for a total value of $41,790.00. Following the completion of the sale, the insider now directly owns 36,710 shares in the company, valued at approximately $1,022,740.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Dustin Finer also recently made the following trade(s):
- On Wednesday, June 2nd, Dustin Finer sold 2,322 shares of Covetrus stock. The stock was sold at an average price of $27.28, for a total value of $63,344.16.
- On Tuesday, May 4th, Dustin Finer sold 1,500 shares of Covetrus stock. The stock was sold at an average price of $30.43, for a total value of $45,645.00.
- On Tuesday, April 6th, Dustin Finer sold 1,500 shares of Covetrus stock. The stock was sold at an average price of $29.38, for a total value of $44,070.00.
CVET traded up $0.36 during trading hours on Thursday, hitting $27.83. The company's stock had a trading volume of 285,178 shares, compared to its average volume of 754,568. Covetrus, Inc. has a fifty-two week low of $15.03 and a fifty-two week high of $40.78. The company has a quick ratio of 1.27, a current ratio of 2.09 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of -349.58, a PEG ratio of 1.74 and a beta of 2.05. The business's 50-day moving average is $28.23.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Clayton Dubilier & Rice LLC increased its position in Covetrus by 32.4% in the 4th quarter. Clayton Dubilier & Rice LLC now owns 33,676,829 shares of the company's stock valued at $967,872,000 after acquiring an additional 8,246,585 shares during the period. BlackRock Inc. increased its position in shares of Covetrus by 6.1% during the 1st quarter. BlackRock Inc. now owns 16,893,323 shares of the company's stock valued at $506,293,000 after purchasing an additional 972,278 shares during the period. Morgan Stanley increased its position in shares of Covetrus by 1.6% during the 1st quarter. Morgan Stanley now owns 11,173,857 shares of the company's stock valued at $334,880,000 after purchasing an additional 175,090 shares during the period. JPMorgan Chase & Co. increased its position in shares of Covetrus by 17.7% during the 1st quarter. JPMorgan Chase & Co. now owns 3,888,222 shares of the company's stock valued at $116,530,000 after purchasing an additional 585,304 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Covetrus by 8.3% during the 1st quarter. Geode Capital Management LLC now owns 1,824,116 shares of the company's stock valued at $54,668,000 after purchasing an additional 139,390 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.
CVET has been the topic of several recent research reports. Barclays initiated coverage on Covetrus in a report on Wednesday, February 17th. They issued an "overweight" rating and a $48.00 price target on the stock. Zacks Investment Research raised Covetrus from a "sell" rating to a "hold" rating in a report on Thursday, May 20th. Finally, Raymond James raised their target price on Covetrus from $31.00 to $39.00 and gave the company an "outperform" rating in a research report on Tuesday, March 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Covetrus has a consensus rating of "Buy" and a consensus price target of $33.40.
Covetrus Company Profile
Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.
Further Reading: After-Hours Trading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is the Beige Book?7 Electric Vehicle (EV) Stocks That Have Real Juice
I’ll start with a disclaimer. You won’t see Tesla (NASDAQ:TSLA) or Nio (NYSE:NIO) on this list. And that’s not because I’m being contrarian. I just view Tesla and Nio as the known quantities in the electric vehicle sector. The goal of this presentation is to help you identify stocks that may be flying under your radar.
Many EV stocks went public in 2020 via a special purpose acquisition company (SPAC). There is both good and bad to that story. The good is that investors have many options for investing in the EV sector. Many of the companies that have entered the market are attempting to carve out a specific niche.
The potentially bad news is that these stocks are very speculative in nature. Whereas companies like Tesla and Nio have a proven (albeit recent) track record, there are things like revenue and orders that investors can analyze. With many of these newly public companies, investors are being asked to buy the story more than the stock and that is always risky.
However, in this special presentation, we’ve identified seven companies that look like they have a story that is compelling enough that investors should be rewarded in 2021.
View the "7 Electric Vehicle (EV) Stocks That Have Real Juice"